ReviewFrontiers in bioengineering and biotechnology2022
Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: Recent advances.
Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 57 citations in OpenAlex.
- Hyaluronic acid-RSC pharmaceutics · 2026Article
- In vitro antitumor efficacy of hyaluronic acid coating for curcumin-loaded zeolitic imidazole frameworks-8 (ZIF-8) versus that of uncoated curcumin-loaded ZIF-8 nanocomposites.Scientific reports · 2026Article
- Nanoparticle carriers in the treatment of intracellular bacterial infections: Current approaches and challenges.International journal of pharmaceutics: X · 2026Review
- Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Molecular cancer · 2026Review
- Chitosan-Based Drug Delivery Systems for Targeted Chemotherapy in Colorectal Cancer: A Scoping Review.Marine drugs · 2025Article
- Advancements in Polysaccharide-Based Nanoparticles for the Treatment of Breast Cancer: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Macrophage-mediated delivery of ganciclovir nanocomplexes inhibits the pathogenicity of Kaposi's sarcoma-associated herpesvirus.Discover oncology · 2025Article
- Global trends and research hotspots in nanodrug delivery systems for breast cancer therapy: a bibliometric analysis (2013-2023).Discover oncology · 2025Article
- Complexed hyaluronic acid-based nanoparticles in cancer therapy and diagnosis: Research trends by natural language processing.Heliyon · 2025Article
- Alleviation of Tumor Invasion by the Development of Natural Polymer-based Low-risk Chemotherapeutic Systems - review on the Malignant Carcinoma Treatments.Current drug delivery · 2025Review
- Optically Controlled Drug Delivery Through Microscale Brain-Machine Interfaces Using Integrated Upconverting Nanoparticles.Sensors (Basel, Switzerland) · 2024Article
- Milk-Derived Extracellular Vesicles: A Novel Perspective on Comparative Therapeutics and Targeted Nanocarrier Application.Vaccines · 2024Review
- Folic acid grafted mixed polymeric micelles as a targeted delivery strategy for tamoxifen citrate in treatment of breast cancer.Drug delivery and translational research · 2024Article
- Article
- Mass balance, metabolic disposition, and pharmacokinetics of a single IV dose of [14C]CA102N in HT-29 xenograft athymic nude mice.Frontiers in pharmacology · 2024Article
- The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer.International journal of molecular sciences · 2023Review
- Review
- Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Hyaluronic Acid-Coated Chitosan Nanoparticles as an Active Targeted Carrier of Alpha Mangostin for Breast Cancer Cells.Polymers · 2023Article
- Natural Biopolymers as Smart Coating Materials of Mesoporous Silica Nanoparticles for Drug Delivery.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most common malignancy among females worldwide, and high resistance to drugs and metastasis rates are the leading causes of death in BC patients. Releasing anti-cancer drugs precisely to the tumor site can improve the efficacy and reduce the side effects on the body. Natural polymers are attracting extensive interest as drug carriers in treating breast cancer. Hyaluronic acid (HA) is a natural polysaccharide with excellent biocompatibility, biodegradability, and non-immunogenicity and is a significant component of the extracellular matrix. The CD44 receptor of HA is overexpressed in breast cancer cells and can be targeted to breast tumors. Therefore, many researchers have developed nano drug delivery systems (NDDS) based on the CD44 receptor tumor-targeting properties of HA. This review examines the application of HA in NDDSs for breast cancer in recent years. Based on the structural composition of NDDSs, they are divided into HA NDDSs, Modified HA NDDSs, and HA hybrid NDDSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.